Zhang X, Liu Y, Tang HF, Jiang F, Chen CL, Wang TT, Gu HZ, Zhao Q, Ma R. Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression. World J Psychiatry 2024; 14(9): 1354-1363 [DOI: 10.5498/wjp.v14.i9.1354]
Corresponding Author of This Article
Rui Ma, MD, Doctor, Department of Pharmacy, The 305 Hospital of People’s Liberation Army, No. A13 Wenjin Street, Xicheng District, Beijing 100017, China. maruipla@126.com
Research Domain of This Article
Integrative & Complementary Medicine
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Psychiatry. Sep 19, 2024; 14(9): 1354-1363 Published online Sep 19, 2024. doi: 10.5498/wjp.v14.i9.1354
Shugan Jieyu capsule effects on peripheral blood micro-124, micro-132, and brain-derived neurotrophic factor in patients with mild to moderate depression
Xian Zhang, Yang Liu, Hua-Fei Tang, Feng Jiang, Chun-Liang Chen, Ting-Ting Wang, Hui-Zhong Gu, Qiang Zhao, Rui Ma
Xian Zhang, Yang Liu, Hua-Fei Tang, Feng Jiang, Chun-Liang Chen, Ting-Ting Wang, Hui-Zhong Gu, Qiang Zhao, Rui Ma, Department of Pharmacy, The 305 Hospital of People’s Liberation Army, Beijing 100017, China
Co-first authors: Xian Zhang and Yang Liu.
Co-corresponding authors: Qiang Zhao and Rui Ma.
Author contributions: Zhang X and Liu Y contributed equally to this work. Zhang X and Liu Y designed the study and performed the experiments; Tang HF, Jiang F, Chen CL, Wang TT, and Gu HZ collected the data; Zhao Q analyzed the data; Ma R prepared the manuscript, they are the co-corresponding authors of this manuscript. All the authors have read and approved the final version of the manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of Hospital of Beijing Armed Police Forces the initiator of the multi-center joint study.
Informed consent statement: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data presented in this study are available on request from the corresponding author.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui Ma, MD, Doctor, Department of Pharmacy, The 305 Hospital of People’s Liberation Army, No. A13 Wenjin Street, Xicheng District, Beijing 100017, China. maruipla@126.com
Received: June 12, 2024 Revised: July 4, 2024 Accepted: August 5, 2024 Published online: September 19, 2024 Processing time: 91 Days and 2.5 Hours
Abstract
BACKGROUND
To assess the effectiveness of Shugan Jieyu capsules on peripheral blood miR-124, miR-132, and brain-derived neurotrophic factor (BDNF) levels in patients with mild to moderate depression following coronary artery intervention [percutaneous coronary intervention (PCI)] for coronary heart disease.
AIM
To evaluate the therapeutic efficacy of Shugan Jieyu capsules and their effects on the peripheral blood levels of miR-124, miR-132, and BDNF in patients with mild to moderate depression following PCI for coronary heart disease.
METHODS
Patients with mild-to-moderate depression of the liver-qi stagnation type after PCI for coronary heart disease at the 305th Hospital of the People’s Liberation Army were enrolled from June 2022 to November 2023 and randomly assigned to two groups: Experimental (treated with Shugan Jieyu capsules) and control (treated with escitalopram oxalate tablets). This study compared the antidepressant effects of these treatments using 17-item Hamilton Rating Scale for Depression (HAMD-17) scores, metabolic equivalents, low-density lipoprotein cholesterol, BDNF, high-sensitivity C-reactive protein levels, miR-124 and miR-132 levels, distribution of immune-related lymphocyte subsets, and traditional Chinese medicine syndrome scores before and after 6 weeks of treatment.
RESULTS
No significant difference was observed in any index between the two groups before treatment (P > 0.05). After treatment, the total efficacy rates were 93.33% and 90.00% in the experimental and control groups, respectively. Experimental group had significantly lower scores for the main and secondary syndromes compared to the control group (P < 0.05). No significant difference was observed in the metabolic equivalents between the two groups before and after treatment (P > 0.05). The levels of low-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and miR-132 were significantly lower, whereas those of miR-124, BDNF, CD3+T lymphocytes, CD3+CD4+T helper lymphocytes, and CD3+CD4+/CD3+CD8+ cells were significantly higher in the experimental group compared to the control group (P < 0.05). The incidence of adverse reactions during experimental group was significantly lower than that in control group (P < 0.05).
CONCLUSION
Shugan Jieyu capsules have good efficacy in patients with mild-to-moderate depression after PCI, and its mechanism may contribute to the regulation of miR-124, miR-132, BDNF levels, and lymphoid immune cells.
Core Tip: The study examines the effects of Shugan Jieyu capsules on patients with mild to moderate depression following percutaneous coronary intervention for coronary heart disease. The results indicate significant improvements in depressive symptoms, biochemical markers such as miR-124, miR-132, and brain-derived neurotrophic factor, as well as immune function. Shugan Jieyu capsules outperformed escitalopram oxalate tablets in reducing depression severity and adverse reactions, suggesting their potential as a safer and more effective treatment alternative for post-percutaneous coronary intervention depression.
